USFDAMay 14, 2026, 08:07 AM
Clene to Submit CNM-Au8 NDA for ALS in Q3 2026; Extends Debt Maturity
AI Summary
Clene Inc. announced plans to submit a New Drug Application (NDA) for CNM-Au8® for ALS under the accelerated approval pathway in Q3 2026, following a successful Type C meeting with the FDA. The company also amended its $10 million convertible debt facility, extending the maturity to August 2027 and eliminating monthly principal and interest payments until then, which is expected to extend its operating runway. For the first quarter of 2026, Clene reported a net loss of $8.1 million and ended the period with $5.9 million in cash and cash equivalents, after completing two registered direct offerings totaling $35 million in gross proceeds.
Key Highlights
- Clene plans to submit NDA for CNM-Au8® for ALS in Q3 2026 via accelerated approval pathway.
- FDA indicated proposed data may support NDA submission for ALS treatment.
- Amended $10 million convertible debt facility, extending maturity to August 2027.
- Deferred monthly principal and interest payments on convertible debt until maturity.
- Completed oversubscribed registered direct offering of over $28 million in January 2026.
- Closed $7 million underwritten registered direct offering with a single investor in May 2026.
- Reported Q1 2026 net loss of $8.1 million, or $0.69 per share.
- Cash and cash equivalents totaled $5.9 million as of March 31, 2026.
Price Impact
More from CLNN